XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Collaborative Arrangements (Tables)
 3 Months Ended
Mar. 31, 2021
Collaborative Arrangements [Abstract]  
Collaboration Arrangements
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20212020
Alliance revenue - Lynparza$228 $145 
Alliance revenue - Koselugo5 — 
Total alliance revenue$233 $145 
Cost of sales (1)
42 28 
Selling, general and administrative40 33 
Research and development29 36 
($ in millions)March 31, 2021December 31, 2020
Receivables from AstraZeneca included in Other current assets
$236 $215 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
417423
(1) Represents amortization of capitalized milestone payments.
(2) Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20212020
Alliance revenue - Lenvima$130 $128 
Cost of sales (1)
47 35 
Selling, general and administrative23 11 
Research and development64 64 
($ in millions)March 31, 2021December 31, 2020
Receivables from Eisai included in Other current assets
$153 $157 
Payables to Eisai included in Accrued and other current liabilities (2)
300 335 
Payables to Eisai included in Other Noncurrent Liabilities (3)
300 600 
(1) Represents amortization of capitalized milestone payments.
(2) Includes accrued milestone and future option payments.
(3) Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20212020
Alliance revenue - Adempas$74 $53 
Net sales of Adempas recorded by Merck55 56 
Total sales$129 $109 
Cost of sales (1)
189 28 
Selling, general and administrative32 15 
Research and development7 25 
($ in millions)March 31, 2021December 31, 2020
Receivables from Bayer included in Other current assets
$68 $65 
Payables to Bayer included in Other Noncurrent Liabilities (2)
400 — 
(1) Includes amortization of intangible assets. Amount in the first quarter of 2021 includes $153 million of cumulative amortization as noted above.
(2) Represents accrued milestone payment.